Elite Pharmaceuticals Inc (ELTP)

[Couch]

Bravo WeeZuhl - to me this a is 5 star ***** Sticky Worthy Post.

I appreciate the willingness to lay out such informed DD, particularly pointing to the distinction between patent protection and FDA marketing exclusivity. I, for one, was confused when Arymo did not get the FDA's full ADT labeling related to the expected reduction of abuse of single entity extended release morphine by the intranasal route due to physicochemical properties. As I'm sure you already know, the company Daiichi Sankyo developed and launched MorphaBond and thus holds FDA exclusivity related to an extended release morphine ADT.

In regards to where Nasrat got the recipe for the hard shell tablet? My money is on Nasrat taking a page from Actavis's playbook including Nasrat watching how Actavis obtained manufacturing contracts from other BPs. If one knows anything about Actavis they were a master at developing generic knock offs of branded products including 4/5 ADT products prior to those branded products losing patent protection. Actavis even manufactured Embeda for Pfizer for a period of time prior to Actavis buying Watson.

Purdue's Oxycontin was one of those generic products Actavis developed. Purdue sued Actavis in 2010 over patent infringement rights and the court case was settled in 2013. Nasrat didn't leave Actavis till 2013. And Elite's Doug Plassche was the one who would've been in charge of overseeing Actavis's manufacturing of its generic OxyContin. Here's what Actavis basically earned in regard to generic OxyContin up to 2015.

The Parsippany, N.J., company, the third-largest generics maker in the world, said it expects more than $100 million in gross profit from generic OxyContin sales through 2015, and smaller contributions to its profit after that.

Elite gets a 15% cut of Epic's generic OxyContin for life. I would imagine Nasrat helping Epic develop a generic version of Purdue's generic OxyContin would garner Elite 15% now wouldn't you.

So Elite has filed a generic Percocet, Narco and soon OxyContin. Nasrat cut his teeth at Alpharma, Watson and Actavis - the third largest generic company in the world at the time he was employed there. It would seem his experience is about to become more than invaluable at Elite in the generic development department alone.

I have become curious. Between Nasrat, Doug Plasche, and Ashok G. Nigalaye - how many generic recipes do they have at their disposal???

It has become abundently clear to me that current Elite investors, with the current PPS, have a five to ten bagger alone in relation to Elite's newer generic pipeline. Nasrat did say he was going to make the existing generic pipeline look rather paltry when compared to what Elite's generic pipeline would look like in the future. It is nice to see Nasrat sticking to his word on the generic pipeline expansion.

NOW if I have a 5/10 bagger on the generic pipeline - what do you suppose we have if/when SequestOx is approved and they move on to Eli 216.....